Onconetix unit Proteomedix launches Proclarix U.S. validation study with Labcorp

Labcorp
Onconetix

Labcorp

LH

0.00

Onconetix

ONCO

0.00
  • Onconetix reported Q1 2026 progress at wholly owned Swiss subsidiary Proteomedix, highlighting two peer-reviewed studies supporting Proclarix use to cut unnecessary prostate biopsies.
  • Proteomedix initiated PRIME, a US multi-center validation study with Labcorp, enrolling first participants with target up to 500 men across multiple ethnicities.
  • European rollout advanced, with Proclarix offered in a UK real-world screening initiative that ran close to 100 tests during Q1, alongside steps toward expansion into Turkey.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130925PRIMZONEFULLFEED9719427) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.